Literature DB >> 11191836

Cannabinoid CB1 receptor-mediated inhibition of acetylcholine release in the brain of NMRI, CD-1 and C57BL/6J mice.

M Kathmann1, B Weber, E Schlicker.   

Abstract

Cannabinoid CB1 receptors occur as presynaptic receptors producing inhibition of neurotransmitter release. To elucidate their physiological role, experiments on tissues from CB1 receptor knockout mice would be helpful. We studied whether CB1 receptor-mediated inhibition of acetylcholine release is detectable in the brain of NMRI mice and of CD-1 and C57BL/6J mice (the latter two strains representing the wild-type strains of the two CB1 receptor knockout mouse models). Brain slices preincubated with [3H]choline were superfused and tritium overflow was evoked electrically (3 Hz) or by introduction of Ca2+ into Ca2+-free K+-rich medium (35 mM) containing tetrodotoxin. The eletrically evoked tritium overflow from NMRI mouse hippocampal slices was inhibited (maximally by 60%) by the cannabinoid receptor agonists CP-55,940 and WIN 55,212-2 but not affected by WIN 55,212-3 (the inactive enantiomer of WIN 55,212-2; pEC50=7.9, 7.4 and <5.5). The concentration-response curve of WIN 55,212-2 was shifted to the right by the CB1 receptor antagonist SR 141716 (apparent pA2=8.6). Compared to hippocampal slices from NMRI mice, WIN 55,212-2 1 microM inhibited the electrically evoked overflow (1) from cortical slices from NMRI mice to a lesser extent and from striatal slices not at all, (2) from hippocampal slices from CD-1 and C57BL/6J mice to an identical extent and (3) from hippocampal slices from Sprague-Dawley rats to at least the same extent. SR 141716 0.32 microM abolished the effect of WIN 55,212-2 1 microM in hippocampal slices from NMRI, CD-1 and C57BL/6J mice and in cortical slices from NMRI mice. The electrically evoked tritium overflow from NMRI mouse hippocampal slices was also inhibited by the muscarinic receptor agonist oxotremorine (maximum effect of 85%; pEC50=6.5) and this effect was antagonized by the muscarinic receptor antagonist AF-DX 384 (apparent pA2=8.3). The Ca2+-evoked tritium overflow from NMRI mouse hippocampal slices was inhibited by WIN 55,212-2 in a manner sensitive to SR 141716. In conclusion, the cholinergic axon terminals of the NMRI mouse hippocampus are endowed with presynaptic CB1 receptors. Such receptors are also detectable in the hippocampus of CD-1 and C57BL/6J mice. The maximum extent of the CB1 receptor-mediated inhibition of acetylcholine release is lower than the maximum effect mediated via the autoreceptor.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11191836     DOI: 10.1007/s002100000304

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  16 in total

1.  Cannabinoid CB(1) receptor-mediated inhibition of hippocampal acetylcholine release is preserved in aged mice.

Authors:  Agnes Redmer; Markus Kathmann; Eberhard Schlicker
Journal:  Br J Pharmacol       Date:  2003-04       Impact factor: 8.739

Review 2.  Microarray technology and its application on nicotine research.

Authors:  Ming D Li; Ozien Konu; Justin K Kane; Kevin G Becker
Journal:  Mol Neurobiol       Date:  2002-06       Impact factor: 5.590

3.  Cannabinoid and cholinergic systems interact during performance of a short-term memory task in the rat.

Authors:  Anushka V Goonawardena; Lianne Robinson; Robert E Hampson; Gernot Riedel
Journal:  Learn Mem       Date:  2010-09-28       Impact factor: 2.460

4.  Genetic and pharmacological approaches to evaluate the interaction between the cannabinoid and cholinergic systems in cognitive processes.

Authors:  S A Bura; A Castañé; C Ledent; O Valverde; R Maldonado
Journal:  Br J Pharmacol       Date:  2007-02-05       Impact factor: 8.739

5.  Cannabinoid CB1 receptor activation, pharmacological blockade, or genetic ablation affects the function of the muscarinic auto- and heteroreceptor.

Authors:  Kirsten Schulte; Nina Steingrüber; Bernd Jergas; Agnes Redmer; Christina Maria Kurz; Rainer Buchalla; Beat Lutz; Andreas Zimmer; Eberhard Schlicker
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-01-04       Impact factor: 3.000

6.  Lack of CB1 receptors increases noradrenaline release in vas deferens without affecting atrial noradrenaline release or cortical acetylcholine release.

Authors:  Eberhard Schlicker; Agnes Redmer; Andre Werner; Markus Kathmann
Journal:  Br J Pharmacol       Date:  2003-08-11       Impact factor: 8.739

Review 7.  Supraspinal modulation of pain by cannabinoids: the role of GABA and glutamate.

Authors:  K Rea; M Roche; D P Finn
Journal:  Br J Pharmacol       Date:  2007-09-10       Impact factor: 8.739

8.  Rivastigmine but not vardenafil reverses cannabis-induced impairment of verbal memory in healthy humans.

Authors:  E L Theunissen; P Heckman; E B de Sousa Fernandes Perna; K P C Kuypers; A Sambeth; A Blokland; J Prickaerts; S W Toennes; J G Ramaekers
Journal:  Psychopharmacology (Berl)       Date:  2014-07-08       Impact factor: 4.530

9.  CB1- and CB2-cannabinoid receptor-independent lipolysis induced by WIN 55,212-2 in male rat adipocytes.

Authors:  Paola Nieri; Rosamiria Greco; Barbara Adinolfi; Maria Cristina Breschi; Enrica Martinotti; Carla Nannetti; Adriano Podestà
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-10-18       Impact factor: 3.000

10.  Biphasic effects of cannabinoids on acetylcholine release in the hippocampus: site and mechanism of action.

Authors:  Eleni T Tzavara; Mark Wade; George G Nomikos
Journal:  J Neurosci       Date:  2003-10-15       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.